HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Zealand Pharma Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Zealand Pharma Intelligence Report

Generated from 2 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 69%

Evidence

12 items

Sources

6

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Zealand Pharma maintains an active intelligence profile across Endocrinology, Obesity, Diabetes. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with moderate portfolio impact. Evidence coverage stands at 69% across 2 tracked sources. Highest-priority development: Drug Trials Snapshots: YARTEMLEA. Regulatory precedent. Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Roche.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    Drug Trials Snapshots: YARTEMLEA

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    Drug Trials Snapshots: PALSONIFY

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    Quantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    Ongoing | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — ZEGALOGUE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — CONZIP (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — DEMEROL (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Commissioner's National Priority Voucher (CNPV) Pilot Program

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA AP — ZEGALOGUE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 39 with buyer quality 7 (Emerging). Competitive pressure: Low. Portfolio impact: Moderate.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Drug Trials Snapshots: YARTEMLEA

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Drug Trials Snapshots: PALSONIFY

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Quantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ZEGALOGUE (SUPPL)

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — CONZIP (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — DEMEROL (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Commissioner's National Priority Voucher (CNPV) Pilot Program

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ZEGALOGUE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Hoffmann-La Roche Evaluates Petrelintide and Enicepatide in Obesity Trial

    Endocrinology · Obesity

  • FDA Grants Priority Review for ZEGALOGUE Supplemental Application

    Endocrinology · Diabetes

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.